Benitec Biopharma (NASDAQ:BNTC) Given “Buy” Rating at HC Wainwright

Benitec Biopharma (NASDAQ:BNTC)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $28.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 73.81% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. Baird R W upgraded shares of Benitec Biopharma to a “strong-buy” rating in a research note on Thursday, December 12th. Robert W. Baird began coverage on Benitec Biopharma in a research report on Friday, December 13th. They set an “outperform” rating and a $30.00 price target on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $17.00 price objective on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Benitec Biopharma presently has an average rating of “Buy” and a consensus target price of $24.43.

Benitec Biopharma Stock Performance

Shares of BNTC stock opened at $16.11 on Monday. The firm has a market capitalization of $377.80 million, a PE ratio of -10.67 and a beta of 0.92. Benitec Biopharma has a 1 year low of $4.75 and a 1 year high of $16.90. The stock has a fifty day moving average of $11.91 and a two-hundred day moving average of $10.97.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19. Equities research analysts predict that Benitec Biopharma will post -1.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Infinitum Asset Management LLC acquired a new stake in shares of Benitec Biopharma during the fourth quarter worth $2,652,000. Suvretta Capital Management LLC increased its stake in Benitec Biopharma by 1.5% in the 4th quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company’s stock worth $113,165,000 after purchasing an additional 130,956 shares in the last quarter. Lion Point Capital LP raised its holdings in Benitec Biopharma by 59.0% during the 4th quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company’s stock worth $783,000 after buying an additional 23,000 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Benitec Biopharma by 198.5% in the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company’s stock worth $33,268,000 after buying an additional 1,739,904 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Benitec Biopharma by 138.4% in the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock worth $448,000 after buying an additional 20,597 shares during the period. Institutional investors and hedge funds own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.